<p>New and emerging treatments with the potential to extend survival are reshaping and extending the management pathway for men with metastatic castration-resistant prostate cancer. To maximise the likely benefit for each individual patient, careful consideration must be given to the timing of treatment, the sequence in which the various agents are used and the proactive management of treatment-related side effects. This article considers the recent advances in this setting, and the associated nursing issues, with reference to the experience of a UK oncology centre.</p>